Global Cell Expansion Technologies Market Research Report 2019

2 Global Cell Expansion Technologies Quarterly Market Size Analysis

• 2.1 Cell Expansion Technologies Business Impact Assessment - COVID-19
  • 2.1.1 Global Cell Expansion Technologies Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Cell Expansion Technologies Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Cell Expansion Technologies Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Cell Expansion Technologies Headquarters and Area Served
• 3.3 Date of Key Players Enter into Cell Expansion Technologies Market
• 3.4 Key Players Cell Expansion Technologies Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Cell Expansion Technologies Segments, By Type

• 4.1 Introduction
  • 1.4.1 Reagents
  • 1.4.2 Media
  • 1.4.3 Sera
  • 1.4.4 Disposables
• 4.2 By Type, Global Cell Expansion Technologies Market Size, 2019-2021

5 Impact of Covid-19 on Cell Expansion Technologies Segments, By Application

• 5.1 Overview
  • 5.5.1 Clinical diagnostics
  • 5.5.2 Drug discovery and development
  • 5.5.3 Regenerative medicine
  • 5.5.4 Others
• 5.2 By Application, Global Cell Expansion Technologies Market Size, 2019-2021
  • 5.2.1 By Application, Global Cell Expansion Technologies Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Becton
  • 7.1.1 Becton Business Overview
  • 7.1.2 Becton Cell Expansion Technologies Quarterly Revenue, 2020
  • 7.1.3 Becton Cell Expansion Technologies Product Introduction
  • 7.1.4 Becton Response to COVID-19 and Related Developments
• 7.2 Dickinson
  • 7.2.1 Dickinson Business Overview
  • 7.2.2 Dickinson Cell Expansion Technologies Quarterly Revenue, 2020
  • 7.2.3 Dickinson Cell Expansion Technologies Product Introduction
  • 7.2.4 Dickinson Response to COVID-19 and Related Developments
• 7.3 GE Healthcare
  • 7.3.1 GE Healthcare Business Overview
  • 7.3.2 GE Healthcare Cell Expansion Technologies Quarterly Revenue, 2020
  • 7.3.3 GE Healthcare Cell Expansion Technologies Product Introduction
  • 7.3.4 GE Healthcare Response to COVID-19 and Related Developments
• 7.4 Thermo Fisher Scientific Inc.
  • 7.4.1 Thermo Fisher Scientific Inc. Business Overview
  • 7.4.2 Thermo Fisher Scientific Inc. Cell Expansion Technologies Quarterly Revenue, 2020
  • 7.4.3 Thermo Fisher Scientific Inc. Cell Expansion Technologies Product Introduction
  • 7.4.4 Thermo Fisher Scientific Inc. Response to COVID-19 and Related Developments
• 7.5 Corning Inc
  • 7.5.1 Corning Inc Business Overview
  • 7.5.2 Corning Inc Cell Expansion Technologies Quarterly Revenue, 2020
  • 7.5.3 Corning Inc Cell Expansion Technologies Product Introduction
  • 7.5.4 Corning Inc Response to COVID-19 and Related Developments
• 7.6 Danaher Corp
  • 7.6.1 Danaher Corp Business Overview
  • 7.6.2 Danaher Corp Cell Expansion Technologies Quarterly Revenue, 2020
  • 7.6.3 Danaher Corp Cell Expansion Technologies Product Introduction
  • 7.6.4 Danaher Corp Response to COVID-19 and Related Developments
• 7.7 Merck Millipore
  • 7.7.1 Merck Millipore Business Overview
  • 7.7.2 Merck Millipore Cell Expansion Technologies Quarterly Revenue, 2020
  • 7.7.3 Merck Millipore Cell Expansion Technologies Product Introduction
  • 7.7.4 Merck Millipore Response to COVID-19 and Related Developments
• 7.8 Terumo BCT
  • 7.8.1 Terumo BCT Business Overview
  • 7.8.2 Terumo BCT Cell Expansion Technologies Quarterly Revenue, 2020
  • 7.8.3 Terumo BCT Cell Expansion Technologies Product Introduction
  • 7.8.4 Terumo BCT Response to COVID-19 and Related Developments
• 7.9 STEMCELL Technologies
  • 7.9.1 STEMCELL Technologies Business Overview
  • 7.9.2 STEMCELL Technologies Cell Expansion Technologies Quarterly Revenue, 2020
  • 7.9.3 STEMCELL Technologies Cell Expansion Technologies Product Introduction
  • 7.9.4 STEMCELL Technologies Response to COVID-19 and Related Developments
• 7.10 Sigma-Aldrich Corp
  • 7.10.1 Sigma-Aldrich Corp Business Overview
  • 7.10.2 Sigma-Aldrich Corp Cell Expansion Technologies Quarterly Revenue, 2020
  • 7.10.3 Sigma-Aldrich Corp Cell Expansion Technologies Product Introduction
  • 7.10.4 Sigma-Aldrich Corp Response to COVID-19 and Related Developments
• 7.11 Miltenyi Biotec
  • 7.11.1 Miltenyi Biotec Business Overview
  • 7.11.2 Miltenyi Biotec Cell Expansion Technologies Quarterly Revenue, 2020
  • 7.11.3 Miltenyi Biotec Cell Expansion Technologies Product Introduction
  • 7.11.4 Miltenyi Biotec Response to COVID-19 and Related Developments
• 7.12 Life Technologies
  • 7.12.1 Life Technologies Business Overview
  • 7.12.2 Life Technologies Cell Expansion Technologies Quarterly Revenue, 2020
  • 7.12.3 Life Technologies Cell Expansion Technologies Product Introduction
  • 7.12.4 Life Technologies Response to COVID-19 and Related Developments
• 7.13 Replicell
  • 7.13.1 Replicell Business Overview
  • 7.13.2 Replicell Cell Expansion Technologies Quarterly Revenue, 2020
  • 7.13.3 Replicell Cell Expansion Technologies Product Introduction
  • 7.13.4 Replicell Response to COVID-19 and Related Developments
• 7.14 Neximmune
  • 7.14.1 Neximmune Business Overview
  • 7.14.2 Neximmune Cell Expansion Technologies Quarterly Revenue, 2020
  • 7.14.3 Neximmune Cell Expansion Technologies Product Introduction
  • 7.14.4 Neximmune Response to COVID-19 and Related Developments
• 7.15 TC Biopharm
  • 7.15.1 TC Biopharm Business Overview
  • 7.15.2 TC Biopharm Cell Expansion Technologies Quarterly Revenue, 2020
  • 7.15.3 TC Biopharm Cell Expansion Technologies Product Introduction
  • 7.15.4 TC Biopharm Response to COVID-19 and Related Developments
• 7.16 Pluristem Therapeutics
  • 7.16.1 Pluristem Therapeutics Business Overview
  • 7.16.2 Pluristem Therapeutics Cell Expansion Technologies Quarterly Revenue, 2020
  • 7.16.3 Pluristem Therapeutics Cell Expansion Technologies Product Introduction
  • 7.16.4 Pluristem Therapeutics Response to COVID-19 and Related Developments
• 7.17 ReNeuron
  • 7.17.1 ReNeuron Business Overview
  • 7.17.2 ReNeuron Cell Expansion Technologies Quarterly Revenue, 2020
  • 7.17.3 ReNeuron Cell Expansion Technologies Product Introduction
  • 7.17.4 ReNeuron Response to COVID-19 and Related Developments
• 7.18 Voria Biomaterials
  • 7.18.1 Voria Biomaterials Business Overview
  • 7.18.2 Voria Biomaterials Cell Expansion Technologies Quarterly Revenue, 2020
  • 7.18.3 Voria Biomaterials Cell Expansion Technologies Product Introduction
  • 7.18.4 Voria Biomaterials Response to COVID-19 and Related Developments
• 7.19 CellProthera
  • 7.19.1 CellProthera Business Overview
  • 7.19.2 CellProthera Cell Expansion Technologies Quarterly Revenue, 2020
  • 7.19.3 CellProthera Cell Expansion Technologies Product Introduction
  • 7.19.4 CellProthera Response to COVID-19 and Related Developments
• 7.20 Cytomatrix
  • 7.20.1 Cytomatrix Business Overview
  • 7.20.2 Cytomatrix Cell Expansion Technologies Quarterly Revenue, 2020
  • 7.20.3 Cytomatrix Cell Expansion Technologies Product Introduction
  • 7.20.4 Cytomatrix Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US